These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15161794

  • 1. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R.
    Diabetes Care; 2004 Jun; 27(6):1394-8. PubMed ID: 15161794
    [Abstract] [Full Text] [Related]

  • 2. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
    [Abstract] [Full Text] [Related]

  • 3. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb 01; 128(3):165-75. PubMed ID: 9454524
    [Abstract] [Full Text] [Related]

  • 4. Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand.
    Rattarasarn C, Aguilar Diosdado M, Soonthornpun S.
    Diabetes Res Clin Pract; 1997 Sep 01; 37(3):193-7. PubMed ID: 9306041
    [Abstract] [Full Text] [Related]

  • 5. The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells.
    Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, Borboni P, Sesti G.
    J Clin Invest; 1999 Aug 01; 104(3):357-64. PubMed ID: 10430617
    [Abstract] [Full Text] [Related]

  • 6. Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes.
    Koch M, Rett K, Volk A, Maerker E, Haist K, Deninger M, Renn W, Häring HU.
    Exp Clin Endocrinol Diabetes; 1999 Aug 01; 107(5):318-22. PubMed ID: 10482045
    [Abstract] [Full Text] [Related]

  • 7. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes.
    El-Sisi AE, Hegazy SK, Metwally SS, Wafa AM, Dawood NA.
    Ther Adv Endocrinol Metab; 2011 Aug 01; 2(4):155-64. PubMed ID: 23148181
    [Abstract] [Full Text] [Related]

  • 8. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC, Cull CA, Frighi V, Holman RR.
    JAMA; 1999 Jun 02; 281(21):2005-12. PubMed ID: 10359389
    [Abstract] [Full Text] [Related]

  • 9. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes.
    Mammarella S, Romano F, Di Valerio A, Creati B, Esposito DL, Palmirotta R, Capani F, Vitullo P, Volpe G, Battista P, Della Loggia F, Mariani-Costantini R, Cama A.
    Hum Mol Genet; 2000 Oct 12; 9(17):2517-21. PubMed ID: 11030756
    [Abstract] [Full Text] [Related]

  • 10. Interaction effect between common polymorphisms in PPARgamma2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity.
    Stumvoll M, Stefan N, Fritsche A, Madaus A, Tschritter O, Koch M, Machicao F, Häring H.
    J Mol Med (Berl); 2002 Jan 12; 80(1):33-8. PubMed ID: 11862322
    [Abstract] [Full Text] [Related]

  • 11. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
    Eurich DT, Simpson SH, Majumdar SR, Johnson JA.
    Pharmacotherapy; 2005 Jun 12; 25(6):810-6. PubMed ID: 15927899
    [Abstract] [Full Text] [Related]

  • 12. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients.
    Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D'Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G.
    J Clin Endocrinol Metab; 2003 Jul 12; 88(7):3368-71. PubMed ID: 12843189
    [Abstract] [Full Text] [Related]

  • 13. The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells.
    Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, Lauro R, Sesti G.
    J Clin Endocrinol Metab; 2000 May 12; 85(5):2004-13. PubMed ID: 10843189
    [Abstract] [Full Text] [Related]

  • 14. Molecular scanning for mutations in the insulin receptor substrate-1 (IRS-1) gene in Mexican Americans with Type 2 diabetes mellitus.
    Celi FS, Negri C, Tanner K, Raben N, De Pablo F, Rovira A, Pallardo LF, Martin-Vaquero P, Stern MP, Mitchell BD, Shuldiner AR.
    Diabetes Metab Res Rev; 2000 May 12; 16(5):370-7. PubMed ID: 11025561
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P, Sugimoto D, Vlajnic A, Kilo C.
    J Diabetes Complications; 2015 May 12; 29(8):1266-71. PubMed ID: 26281972
    [Abstract] [Full Text] [Related]

  • 16. The Gly972-->Arg IRS-1 variant is associated with type 1 diabetes in continental Italy.
    Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D'Alfonso R, Patera I, Cappa M, Nisticò L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R.
    Diabetes; 2003 Mar 12; 52(3):887-90. PubMed ID: 12606535
    [Abstract] [Full Text] [Related]

  • 17. Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.
    Zychma MJ, Gumprecht J, Strojek K, Grzeszczak W, Moczulski D, Trautsolt W, Karasek D.
    Med Sci Monit; 2002 Jul 12; 8(7):CR512-5. PubMed ID: 12118200
    [Abstract] [Full Text] [Related]

  • 18. An overview of metformin in the treatment of type 2 diabetes mellitus.
    Davidson MB, Peters AL.
    Am J Med; 1997 Jan 12; 102(1):99-110. PubMed ID: 9209206
    [Abstract] [Full Text] [Related]

  • 19. IRS1 G972R missense polymorphism is associated with failure to oral antidiabetes drugs in white patients with type 2 diabetes from Italy.
    Prudente S, Morini E, Lucchesi D, Lamacchia O, Bailetti D, Mercuri L, Alberico F, Copetti M, Pucci L, Fariello S, Giusti L, Cignarelli M, Penno G, De Cosmo S, Trischitta V.
    Diabetes; 2014 Sep 12; 63(9):3135-40. PubMed ID: 24947357
    [Abstract] [Full Text] [Related]

  • 20. Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC8 gene: response to appropriate therapy.
    Reilly F, Sanchez-Lechuga B, Clinton S, Crowe G, Burke M, Ng N, Colclough K, Byrne MM.
    Diabet Med; 2020 May 12; 37(5):876-884. PubMed ID: 31562829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.